drugset / Trial / NCT00305422

Effect of Quetiapine on Negative Symptoms and Cognition

NCT00305422

Phase 3 Completed 45 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to investigate the outcome on negative symptoms of schizophrenic patients during therapy with quetiapine or risperidone.

Timeline

Start
2001-11
Primary completion
Completion
2003-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Quetiapine Small molecule
Subject Risperidone Other / unclassified

Indications